Sangon Biotech and Thermo Fisher Scientific Expand Strategic Collaboration to Chromatography and Mass Spectrometry, Bolstering IVD and Biopharma Solutions

This collaboration, building on the foundation of the initial strategic cooperation agreement signed by both parties on August 16, 2023, expands the scope of cooperation from the field of genetic science to the field of chromatography and mass spectrometry. Relying on Thermo Fisher Scientific's globally leading chromatography and mass spectrometry technology and Sangon Biotech's advanced industrial operations and localization advantages, both parties will jointly promote active exploration and breakthroughs across the entire biotechnology field, particularly in enhancing quality control for industrial production and providing solutions for in vitro diagnostics and biopharmaceutical applications.

This strategic cooperation will significantly enhance Sangon Biotech's quality control capabilities and throughput in the production of core raw materials for upstream medical diagnostics, including Oligo synthesis.

Mark Smedley, Senior Vice President of Thermo Fisher Scientific and President of Asia Pacific and Latin America, Ms. Wang Luojia, CEO of Sangon Biotech (Shanghai) Co., Ltd., and representatives from Novo Holdings, an investor in Sangon Biotech, attended the signing ceremony.

The chromatography and mass spectrometry business boasts an extremely comprehensive product line in the industry, fully covering analytical needs for various types of testing, bringing infinite possibilities for bio-application in the future.